Glenmark Pharmaceuticals Ltd vs Pharmaids Pharmaceuticals Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 03, 2026

Key Highlights

The Latest Trading Price of Glenmark Pharmaceuticals Ltd is ₹ 2034 as of 17 Feb 12:23 . The P/E Ratio of Glenmark Pharmaceuticals Ltd changed from 13.3 on March 2022 to 13.5 on March 2021 . This represents a CAGR of 0.30% over 5 yearsThe P/E Ratio of Pharmaids Pharmaceuticals Ltd changed from 89.4 on March 2022 to 0 on March 2021 . This represents a CAGR of -100.00% over 5 years The Market Cap of Glenmark Pharmaceuticals Ltd changed from ₹ 12477 crore on March 2022 to ₹ 13108 crore on March 2021 . This represents a CAGR of 0.99% over 5 yearsThe Market Cap of Pharmaids Pharmaceuticals Ltd changed from ₹ 12.9 crore on March 2022 to ₹ 0 crore on March 2021 . This represents a CAGR of -100.00% over 5 years The revenue of Glenmark Pharmaceuticals Ltd for the Dec '25 is ₹ 3945 crore as compare to the Sep '25 revenue of ₹ 6247 crore. This represent the decline of -36.85% The revenue of Pharmaids Pharmaceuticals Ltd for the Dec '25 is ₹ 5.51 crore as compare to the Sep '25 revenue of ₹ 11.63 crore. This represent the decline of -52.62% The ebitda of Glenmark Pharmaceuticals Ltd for the Dec '25 is ₹ 729.88 crore as compare to the Sep '25 ebitda of ₹ 1175 crore. This represent the decline of -37.89% The ebitda of Pharmaids Pharmaceuticals Ltd for the Dec '25 is ₹ -2.83 crore as compare to the Sep '25 ebitda of ₹ -2.3 crore. This represent the growth of 23.04% The net profit of Glenmark Pharmaceuticals Ltd changed from ₹ 340.24 crore to ₹ 403.23 crore over 7 quarters. This represents a CAGR of 10.19% The net profit of Pharmaids Pharmaceuticals Ltd changed from ₹ -3.12 crore to ₹ -2.65 crore over 7 quarters. This represents a CAGR of -8.91% The Dividend Payout of Glenmark Pharmaceuticals Ltd changed from 4.28 % on March 2021 to 4.38 % on March 2025 . This represents a CAGR of 0.46% over 5 yearsThe Dividend Payout of Pharmaids Pharmaceuticals Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 years .

About Glenmark Pharmaceuticals Ltd

Glenmark Pharmaceuticals Limited was incorporated on November 18, 1977.
The Company is actively involved in the discovery of new molecules both NCEs (new chemical entity) and NBEs (new biological entity).
It is engaged in the business of development, manufacture and marketing of pharmaceutical products both formulation and active pharmaceuticals ingredients to regulated and semi-regulated markets.
The Company's research and development facilities are located at Mahape, Sinnar and Taloja and manufacturing facilities are located at Nasik, Colvale, Baddi, Nalagarh, Sikkim, Indore and Aurangabad in India. The company has several molecules in various stages of pre-clinical and clinical development primarily focused in the areas of Oncology, Respiratory and Dermatology.
Its branded generics business has a significant presence in markets across emerging economies including India.

About Pharmaids Pharmaceuticals Ltd

Pharmaids Pharmaceuticals Limited, incorporated in March, 1989 at Hyderabad, Telangana were suppliers of Quality Grade range of speciality chemicals, skin care, hospital care and generic products in the areas of Orthopedic, Neuro and Gastro etc.
The technical team used quality proven chemical compounds and standard processing methods maintaining proper hygiene standards.The Company is engaged in the business of contract research and manufacturing services. Emergent Bio Naturals Limited (EBNL) was amalgamated with the Company in 2019-20 and the Scheme of Amalgamation was effective on September 27, 2019.
Pursuant to the Scheme, 69,05,734 Equity Shares were allotted to Shareholders of Emergent Bio Naturals Limited on November 27, 2019. The Company acquired 25.5% stake as 1st tranche in Anugraha Chemicals, a Partnership Firm, registered under Karnataka Partnership Rules, 1954 on February 1, 2023.

FAQs for the comparison of Glenmark Pharmaceuticals Ltd and Pharmaids Pharmaceuticals Ltd

Which company has a larger market capitalization, Glenmark Pharmaceuticals Ltd or Pharmaids Pharmaceuticals Ltd?

Market cap of Glenmark Pharmaceuticals Ltd is 67,884 Cr while Market cap of Pharmaids Pharmaceuticals Ltd is 104 Cr

What are the key factors driving the stock performance of Glenmark Pharmaceuticals Ltd and Pharmaids Pharmaceuticals Ltd?

The stock performance of Glenmark Pharmaceuticals Ltd and Pharmaids Pharmaceuticals Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Glenmark Pharmaceuticals Ltd and Pharmaids Pharmaceuticals Ltd?

As of May 3, 2026, the Glenmark Pharmaceuticals Ltd stock price is INR ₹2405.55. On the other hand, Pharmaids Pharmaceuticals Ltd stock price is INR ₹29.67.

How do dividend payouts of Glenmark Pharmaceuticals Ltd and Pharmaids Pharmaceuticals Ltd compare?

To compare the dividend payouts of Glenmark Pharmaceuticals Ltd and Pharmaids Pharmaceuticals Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.